NCT07526857

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy: A12 Month Multimodal Imaging Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 60 (actual)
• Sponsor: Federico II University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up

Conditions

• Diabetic Retinopathy, DR

Interventions

Type	Name	Description
DRUG	Faricimab Injection [Vabysmo]	One group treated with faricimab and the other one treated with Aflibercept
DRUG	Aflibercept (2.0 mg)	Aflibercept 2 mg intravitreal injection

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-01-01
• Completion: 2026-01-01
• First posted: 2026-04-13
• Last updated: 2026-04-13

Locations

1 site across 1 country: Italy